Company: SMNR
Filing Date: 2025-07-02
Form Type: S-4/A
Source: 0001193125-25-154936
Chunk: 637

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-02
Form: S-4/A
Chunk 637
---
 options exercisable within 60 days of May 30, 2025 (assuming approval of the Option Exchange Proposal and closing of the Business Combination). |

| (6) | Jiandong (Peter) Xu is the manager and controlling member of the Sponsor. As such, each of the Sponsor and Mr. Xu may be deemed to share beneficial ownership of the ordinary shares held directly by the Sponsor. Mr. Xu disclaims any beneficial ownership of the ordinary shares held directly by the Sponsor, and disclaims any beneficial ownership of such shares other than to the extent of any pecuniary interest each may have therein, directly or indirectly. The business address of the Sponsor is 437 Madison Avenue, 27th Floor, New York, New York 10022. |

| (7) | Consists of shares issuable upon separation of the Denali Private Placement Units which will automatically occur at Closing. |

| (8) | Consists solely of founder shares. |

| (9) | Consists of (i) 1,432,500 shares of New Semnur Common Stock based on the Exchange Ratio, (ii) 510,000 shares of New Semnur Common Stock issued upon the automatic separation of the Denali Private Placement Units into its component parts upon the closing of the Business Combination and (iii) 167,337 shares of New Semnur Common Stock issued upon the assumed conversion of the Working Capital Loans in connection with Closing. |

| (10) | The business address of Scilex is 960 San Antonio Road, Palo Alto, CA 94303. |

| (11) | Consists of (i) 200,000,000 shares of New Semnur Common Stock issued as Merger Consideration (which number includes the 5,000,000 shares of Semnur Common Stock contributed to Scilex Bio (which is controlled by Scilex) on April 17, 2025 (which will be converted into 6,250,000 shares of New Semnur Common Stock as Merger Consideration in connection with the Business Combination pursuant to the terms of the Merger Agreement)), (ii) 600,000 shares of New Semnur Common Stock issued as Preferred Consideration and (iii) 18,000 shares of New Semnur Common Stock issued upon the assumed conversion of the Scilex Convertible Note in connection with Closing, which is the maximum number of shares that may be issued upon the conversion of the Scilex Convert